Synergy Pharmaceuticals Highlights Mechanistic Features of Plecanatide, a Novel Investigational Drug for Chronic Idiopathic Constipation
22 oct. 2012 17h00 HE
|
Synergy Pharmaceuticals
NEW YORK, Oct. 22, 2012 (GLOBE NEWSWIRE) -- Synergy Pharmaceuticals Inc. (Nasdaq:SGYP), a developer of new drugs to treat gastrointestinal disorders and diseases, today announced the preclinical...
Synergy Pharmaceuticals Initiates Dosing of Healthy Volunteers in Phase I Trial of SP-333, a Second-Generation GC-C Agonist to Treat Ulcerative Colitis
22 oct. 2012 06h00 HE
|
Synergy Pharmaceuticals
NEW YORK, Oct. 22, 2012 (GLOBE NEWSWIRE) -- Synergy Pharmaceuticals Inc. (Nasdaq:SGYP), a developer of new drugs to treat gastrointestinal disorders announced today that on October 19, 2012 the...
Synergy Pharmaceuticals Files IND for SP-333, a Developmental Drug for Gastrointestinal Diseases
12 sept. 2012 08h39 HE
|
Synergy Pharmaceuticals
NEW YORK, Sept. 12, 2012 (GLOBE NEWSWIRE) -- Synergy Pharmaceuticals, Inc. (Nasdaq:SGYP), a developer of new drugs to treat gastrointestinal (GI) disorders and diseases, announced today that an...
Synergy Pharmaceuticals Acquires FV-100 Shingles Drug From Bristol-Myers Squibb Company
23 août 2012 16h45 HE
|
Synergy Pharmaceuticals
NEW YORK, Aug. 23, 2012 (GLOBE NEWSWIRE) -- Synergy Pharmaceuticals Inc. (Nasdaq:SGYP), a developer of new drugs to treat gastrointestinal disorders and diseases, today announced that it has signed an...
Synergy Pharmaceuticals, Inc. Completes Screening and Planned Enrollment in Phase IIb/III Study in Chronic Idiopathic Constipation Patients
14 août 2012 05h00 HE
|
Synergy Pharmaceuticals
NEW YORK, Aug. 14, 2012 (GLOBE NEWSWIRE) -- Synergy Pharmaceuticals Inc. (Nasdaq:SGYP), a developer of new drugs to treat gastrointestinal disorders announced today that its Phase IIb/III plecanatide...
Synergy Pharmaceuticals to Present at Canaccord Genuity 32nd Annual Growth Conference
09 août 2012 07h00 HE
|
Synergy Pharmaceuticals
NEW YORK, Aug. 9, 2012 (GLOBE NEWSWIRE) -- Synergy Pharmaceuticals, Inc. (Nasdaq:SGYP), a developer of new drugs to treat gastrointestinal disorders and diseases, today announced that its President...
Synergy Pharmaceuticals Signs Definitive Agreement to Acquire Callisto Pharmaceuticals
20 juil. 2012 18h13 HE
|
Synergy Pharmaceuticals
NEW YORK, July 20, 2012 (GLOBE NEWSWIRE) -- Synergy Pharmaceuticals Inc. (Nasdaq:SGYP) and Callisto Pharmaceuticals, Inc. (OTCBB:CLSP) announced today that they have entered into a definitive merger...
Synergy Pharmaceuticals Added to the Russell 3000(R), Russell Global, and Russell Microcap Indexes
25 juin 2012 09h15 HE
|
Synergy Pharmaceuticals
NEW YORK, June 25, 2012 (GLOBE NEWSWIRE) -- Synergy Pharmaceuticals Inc. (Nasdaq:SGYP) (Nasdaq:SGYPU) (Nasdaq:SGYPW), a developer of new drugs to treat gastrointestinal disorders and diseases, today...
Synergy Pharmaceuticals to Present at 2012 BIO International Convention
13 juin 2012 09h15 HE
|
Synergy Pharmaceuticals
NEW YORK, June 13, 2012 (GLOBE NEWSWIRE) -- Synergy Pharmaceuticals, Inc. (Nasdaq:SGYPD) (Nasdaq:SGYPU) (Nasdaq:SGYPW), a developer of new drugs to treat gastrointestinal disorders and diseases, today...
Synergy Pharmaceuticals Announces Exercise of Remainder of Over-Allotment Option by Aegis Capital Corp. Bringing Total Gross Proceeds to $51.75 Million
06 juin 2012 12h53 HE
|
Synergy Pharmaceuticals
NEW YORK, June 6, 2012 (GLOBE NEWSWIRE) -- Synergy Pharmaceuticals Inc. (Nasdaq:SGYP), a developer of new drugs to treat gastrointestinal disorders and diseases, announced the exercise of the...